CVAC Stock Summary and Trading Ideas (Curevac N.V. - | NASDAQ:CVAC)

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Curevac N.V. - trades on the NASDAQ stock market under the symbol CVAC.

As of January 28, 2026, CVAC stock price was flat at $4.66 with million shares trading.

CVAC has a beta of 1.29, meaning it tends to be more sensitive to market movements. CVAC has a correlation of 0.20 to the broad based SPY ETF.

CVAC has a market cap of $1.05 billion. This is considered a Small Cap stock.

Last quarter Curevac N.V. - reported $63 million in Revenue and $1.41 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $1.58.

In the last 3 years, CVAC traded as high as $12.48 and as low as $2.22.

CVAC has outperformed the market in the last year with a return of +23.3%, while the SPY ETF gained +17.1%. However, in the most recent history, CVAC shares have underperformed the stock market with its stock returning -13.4% in the last 3 month period and 0.0% for the last 2 week period, while SPY has returned +1.7% and +0.1%, respectively.

CVAC support price is $4.60 and resistance is $4.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVAC shares will trade within this expected range on the day.